-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Within the histology of non-alcoholic fatty liver disease (NAFLD), the mortality and prognosis of liver and non-liver outcomes are not yet clear
.
Recently, a research article was published in the top medical journal NEJM.
Researchers prospectively followed up a multicenter patient population, including the complete histological map of NAFLD
.
The researchers aimed to compare the incidence of death and other outcomes in patients with different baseline histological characteristics
.
A total of 1773 adults with NAFLD were followed up for a median of 4 years in the study
.
All-cause mortality increases with the increase in fibrosis stages (0.
32 deaths per 100 people per year in F0 to F2 [no, mild or moderate fibrosis], 0.
Compared with patients with F0 to F2 fibrosis, patients with F4 fibrosis with type 2 diabetes (7.
53 vs.
4.
45 per 100 person-years), the estimated glomerular filtration rate is reduced by more than 40% (2.
98 per 100 person-years) vs.
0.
97 events) also have a higher incidence
.
The incidence of cardiac events and non-liver cancer is similar in each stage of fibrosis
.
diabetes
In this prospective study involving NAFLD patients, fibrosis stages F3 and F4 were associated with an increased risk of liver-related complications and death
.
.
Original source:
